The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.
The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback